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IDOhasbeenreportedtoinduceimmunotoleranceandpromotemetastasisinsolidmalignancy,butthemechanismsinvolvedwere
not fully understood. In this study, the expression of IDO in primary breast cancer was examined and the correlation between the
expression levels of IDO and the densities of Foxp3+ Tregs in situ was studied. The IDO stably-expressing CHO cells(IDO/CHO)
were generated to evaluate the induction of Foxp3+ Tregs after coculturing with CD3+ Tc e l l sin vitro. The IDO expression in
cancer was higher than that in benign diseases both at RNA and protein levels. The IDO expression was signiﬁcantly upregulated
in tumors of more advanced stages and with more extensive lymph node metastasis, and displayed positive linear correlation with
the density of Foxp3+ Tregs. We further demonstrated that CD4+CD25+CD127− Tregs could be ampliﬁed by coculturing CD3+
T cells with IDO/CHO cells in vitro which displayed increasing Foxp3 expression both at mRNA and protein levels. Our results
implied that up-regulation of IDO in primary breast cancer may inhibit local immune surveillance and promote metastasis by
favoring development and inﬁltration of Foxp3+ Tregs in the tumor microenvironment.
1.Introduction
Breast cancer is the most common solid malignancy in wom-
enworldwide. Asubstantialfractionofbreastcancerpatients
develop distant metastases shortly after diagnosis. Metastatic
breast cancer is associated with poor prognosis with shorter
survivaltimeandrefractorinesstotherapies.Previousstudies
have proposed the mechanisms of early metastasis, including
overexpression of growth factor receptors and resistant
to apoptosis [1, 2], downregulation of adherent molecu-
les during epithelial-mesenchymal transition (EMT) [3–
5], degradation of extracellular matrix after activation of
matrix metalloproteinases (MMPs) [6, 7], enhanced tumor
angiogenesis [8, 9], and inhibition of eﬀective antitumor
immunity [10, 11]. Breast cancer cells can evade the immune
attack through a variety of complex mechanisms, among
which tumor-derived immunosuppression resulting from
upregulation of metabolistic enzymes, such as indoleamine
2,3-dioxygenase(IDO),hasshownacrucialroleintherecent
studies [12–15].
IDO is a rate-limiting enzyme in the catabolic process
of extrahepatic tryptophan which is an essential amino
acid for T-cell proliferation and activation. Deprivation of
tryptophan in the microenvironment directly aﬀects the
cytotoxicityandcytokinesecretionofTcells.Inaddition,the
toxic metabolites generatedfrom tryptophan via the Kynure-
nine pathway directly induce T-cell apoptosis in vitro [16].
It is also reported that IDO may inhibit T-cell immunity
by inducing diﬀerentiation and maturation of CD4+CD25+
regulatory T cells (Tregs) [17]. Therefore, IDO has been2 Clinical and Developmental Immunology
implicated in the development of autoimmune diseases, reg-
ulation of transplantation immunity, and maintenance of
maternal-fetal tolerance [18].
Recent studies demonstrated that the expression level of
IDO increased in many types of human tumors, including
cancers of the lungs, prostate, pancreas, and cervical car-
cinoma. Tumor-derived IDO dramatically inhibits local T-
cell-dependent antitumor immunity and facilitates tumor
metastasis [19, 20]. Our previous studies, along with work
from other groups, demonstrated that the proportion of
CD4+CD25+ Treg subset increased in breast cancer patients,
with strong correlations with the histological grade and
the tumor size [21, 22]. However, it is not clear if the
increase of CD4+CD25+ Tregs in situ is correlated with the
upregulated expression of IDO in tumor cells. In this study,
the expression of IDO at both mRNA and protein levels
were examined in 26 cases of primary breast cancer and
10 cases of benign breast diseases. The correlation between
IDO expression levels and the densities of Foxp3+ Tregs in
the primary tumor tissues (PTs) and tumor-draining lymph
nodes (TDLNs), as well as various clinical and pathological
indexes of the patients were investigated. Our data indicated
that the expression of IDO in breast cancer PTs was higher
than that in benign disease tissue, but lower than that in
TDLNs. IDO was predominantly expressed in cancer cells
and modestly expressed in hyperplastic ductal cells and some
myeloid cell-like karyocytes in TDLNs. The expression of
IDO in PTs was positively linearly correlated to the density
of Foxp3+ Tregs in PTs and TDLNs and was signiﬁcantly
higher in tumors of more advanced stages and with more
extensive lymph node metastasis. In order to ﬁnd out if
high level of IDO can induce ampliﬁcation of Foxp3+
Tregs, we cocultured CD3+ T cells with IDO+ CHO cells
(IDO/CHO) in vitro. The proportion and absolute number
of CD4+CD25+CD127− Tregs increased after coculturing
CD3+ T cells with IDO/CHO for 7 days, along with elevated
Foxp3 expression at mRNA and protein levels in the CD3+
T cells. These results suggested that upregulation of IDO
in breast cancer cells may lead to increased recruitment of
CD4+CD25+ Tregs into the tumor microenvironment and
thus inhibit the local immune surveillance and promote
metastasis. Therefore, novel IDO-targeted therapies may
provide a new direction for the treatment of breast cancer.
2.MaterialsandMethods
2.1. Patients. Fresh and paraﬃn-embedded samples, includ-
ing primary tumors, TDLNs, and normal adjacent tissues
were collected from 26 cases of breast cancer patients who
were treated with radical mastectomy for breast cancer at the
Department of Breast Oncology of Tianjin Cancer Institute
& Hospital from June to December, 2009. All patients
included 25 females and 1 male with a median age of
50 (31∼70) years old, among whom 21 cases of invasive
ductal carcinoma, 2 cases of invasive lobular carcinoma,
1 case of invasive micropapillary carcinoma, 1 case of mu-
cinous carcinoma, and 1 case of secretory carcinomas were
diagnosed pathologically based on the 2003 WHO classi-
ﬁcation of breast tumor. According to the 6th edition of
the AJCC Cancer Staging Manual, all patients included 2
cases of stage I, 13 cases of stage IIA, 7 case of stage IIB,
3 cases of stage IIIA, and 1 case of stage IIIC. Other 10
patients with benign breast diseases, including 7 cases of
breast ﬁbroadenoma and 3 cases of lobular hyperplasia were
enrolledascontrol.Thisresearchprojectwasapprovedbythe
Ethics Committee of Tianjin Cancer Institute and Hospital.
Written consents were obtained from each patient.
2.2.Immunohistochemistry(IHC). Formaldehyde-ﬁxed,par-
afﬁn-embedded PTs and TDLNs samples were sectioned
into 4μm slices and aﬃxed on glass slides. The immuno-
histochemical staining was performed according to the in-
struction manuals. Brieﬂy, after being heated for half an
hour at 56◦C, the samples were deparaﬃnized in xylene and
rehydrated through graded alcohol. Antigens were retrieved
by heating in citrate buﬀer for a total of 20 minutes. En-
dogenous peroxidase activity was quenched in a bath of
methanol andhydrogenperoxide for30 minutes.Allsamples
were incubated overnight at 4◦C with mouse anti-human
Foxp3 monoclonal antibody (Clone PCH101, eBioscience,
San Diego, Calif, USA) and mouse anti-human IDO mon-
oclonal antibody (Clone 10.1, Chemicon, Temecula, Calif,
USA) at concentrations of 1:1000 and 1:500, respectively.
These antibodies were detected by a biotinylated secondary
antibody (goat anti-mouse IgG-HRP, sc-2302, Santa Cruz,
Calif, USA) labeled with streptavidin-horseradish peroxidase
(HRP), with the use of a DAB staining kit (Maixin Biotech-
nology, Fuzhou, China). For negative control, the primary
antibodywassubstitutedwithPBS.Positivecellswerestained
brownish yellow in the cytoplasm (IDO-positive staining) or
nucleus (Foxp3-positive staining). Two indicators were used
to describe the protein expression of IDO and Foxp genes:
staining rate (SR) and staining index (SI). The SRs referred
to the percentages of positive samples in all samples. The
SIs referred to the percentages of positively stained cells
in each sample which were calculated using the following
formula: (SI = number of positively stained cells/total
number of counted cells ×100%). The SI was determined
upon the average of at least ﬁve high-powered ﬁelds (400x
magniﬁcation). An Olympus BX51 microscope was used for
image acquisition and data analysis.
2.3. Establishment of Stable IDO+ CHO Transfectants. A
1225kb fragment encoding the entire open reading frame
(ORF) of human IDO gene was ampliﬁed by RT-PCR
methodusingtotalRNAisolatedfromMDA-MB-435sbreast
cancer cells as template. The PCR product was ﬁrstly cloned
into the pMD19-T Simple Vector (Takara, Japan) and then
subcloned into the pIRES2-EGFP vector (Clontech, Moun-
tainView, Calif, USA) to generate a recombinant expression
plasmid pIRES2-EGFP-IDO. The CHO cells were transfected
with pIRES2-EGFP-IDO using a standard electroporation
method (ﬁeld strength of 350V/cm, 60μs, 1 pulse), and
IDO+ CHOtransfectants(CHO/IDO)wereselectedbyG418
(1mg/mL, Invitrogen, Carlsbad, Calif, USA) in RPMI 1640
medium supplemented by 10% FBS (Hyclone, Calif, USA)
as described previously [23]. CHO cells transfected with
pIRES2-EGFP (CHO/EGFP) were used as negative control.Clinical and Developmental Immunology 3
Table 1: Primers for real-time quantitative RT-PCR.
Gene name Primer sequences Product size
IDO UP: 5 -CATCTGCAAATCGTGACTAAG-3 
188bp
DP: 5 -CAGTCGACACATTAACCTTCCTTC-3 
Foxp3 UP: 5 -CCCACTTACAGGCACTCCTC-3 
486bp
DP: 5 -CTTCTCCTTCTCCAGCACCA-3 
β-actin UP: 5 -TGGCACCCAGCACAATGAA-3 
186bp
DP: 5 -CTAAGTCATAGTCCGC CTAGAAGCA-3 
N o t e :U P :u p s t r e a mp r i m e r ;D P :d o w n s t r e a mp r i m e r .
2.4. Coculture of CHO/IDO Cells and CD3+ TC e l l s .The
CD3+ Tcellsinperipheralbloodmononuclearcells(PBMCs)
of breast cancer patients were puriﬁed using Human Pan T-
cell Isolation Kit II (Miltenyi Biotec, Germany) according to
the manufacturer’s instructions. 1 × 105 CHO/IDO cells and
CHO/EGFP cells were seeded in a 24-well plate and cocul-
tured with 2 × 106 puriﬁed T cells in complete RPMI 1640
medium supplemented with 10% FBS and 50U/mL rhIL-2
(PeproTech, USA) at 37◦Ci na5 %C O 2 incubator. Unstim-
ulated T cells cocultured in complete RPMI 1640 medium
supplemented with 10% FBS and 50U/mL rhIL-2 were used
as control. The nonadherent T cells under diﬀerent treat-
mentswereharvested7dayslaterforﬂowcytometryanalysis,
quantitativee real time RT-PCR, and Western Blot analysis.
2.5. Flow Cytometry Analysis. The proportions and absolute
counts of Tregs in T cells cocultured with CHO/IDO or
CHO/EGFPcellsfor7days,aswellasthecontrolTcellswere
detected by ﬂow cytometry using FITC labeled anti-human
CD25, PE labeled anti-human CD127, and PerCP-Cy5.5
labeled anti-human CD4 (BD Biosciences Pharmingen, San
Diego,Calif,USA)inTrueCounttubes(BDPharmingen,San
Diego, Calif). The isotype-matched IgG1 was used as nega-
tive control to eliminate nonspeciﬁc staining. 1 × 105 cells
were incubated with antibodies for 30min on ice in dark.
Then, the cells were washed twice with PBS containing 0.2%
BSA, ﬁxed using 1% paraformaldehyde and analyzed using
a FACSAria ﬂow cytometry (Becton Dickinson, Mountain
View, Calif). At least 50,000 events were acquired for each
analysis. All samples were measured at least three times.
2.6. Quantitative Real-Time RT-PCR (qRT-PCR) Assay. The
mRNA expression of IDO gene in PTs, TDLNs, and normal
adjacent tissues, as well as the mRNA expression of forehead
transcription factor 3 (Foxp3) gene in stimulated and un-
stimulated T cells was analyzed using quantitative real-time
RT-PCR. The total RNA was extracted using Trizol Reagent
(Invitrogen, Carlsbad, Calif, USA) and reverse transcribed
to cDNA using MMLV reverse transcriptase (Promega,
Madison, Wis, USA). The expression levels of target genes
were quantiﬁed using the SYBR Premix Ex Taq system (Tak-
ara Bio, Tokyo, Japan) following the manufacturer’s instruc-
tions. The primers of IDO, Foxp3, and β-actin were listed in
Table 1.Thethermalcyclingprogramwaslistedbelow:initial
denaturalization at 94◦Cf o r5m i n u t e s ,9 4 ◦C for 30 seconds,
58◦C for 30 seconds, and 72◦C for 45 seconds for 35 cycles;
afterthelastcycle,72◦Cfor10minut es.Thepr oductsofPCR
reactions were analyzed by agarose gel electrophoresis. The
relative amounts of IDO and Foxp3 genes were normalized
by β-actin and calculated using the formula: 2−ΔCt(ΔCt =
CtFoxp3 −Ctβ-actin). All tests were repeated at least four times.
2.7. Western Blot. The protein expression of Foxp3 in T
cells cocultured with CHO/IDO or CHO/EGFP cells for 7
days, as well as in the control unstimulated T cells, was
analyzed using Western Blot analysis. T cells were washed
using PBS and lysed in lysis buﬀer (50mM Tris-HCl, pH
7.4; 1% NP-40; 0.25% sodium deoxycholate; 150mM NaCl,
1mM EDTA, 1mM Na3VO4,1m MP M S F ,1m MN a Fa n d
1μg/mL of aprotinin and leupeptin, pepstatin) on ice. After
centrifugation, soluble cellular protein concentration was
determined using Micro BCA Protein Assay Kit (Pierce
Biotechnology, Ill, USA). The proteins were separated on
SDS-PAGE and transferred to PVDF membranes. The mem-
brane was incubated with rabbit polyclonal anti-Foxp3 anti-
body (BioLegend, San Diego, Calif, USA) overnight at 4◦C.
Then, the membrane was incubated with HRP-conjugated
mouse secondary antibodies (Zhongshanjinqiao, Beijing,
China) for 1h at room temperature. Bound HRP was
detected by using SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology, Ill, USA). The intensity of
bands was recorded using the ChemiDoc XRS imaging sys-
tem and analyzed using Quantity One software (Bio-Rad
Laboratories, Hercules, Calif, USA).
2.8. Statistical Analysis. All data were presented as mean ±
standard deviation (SD). The statistical analysis was per-
formed using a SPSS 13.0 software package. The one-way
single factor analysis of variance (ANOVA) was used for the
comparison of the quantitative data, and the chi-square (χ2)
test was used for the comparison of the qualitative data.
TheSpearman’srank-ordertestandlinearregressionanalysis
were used to assess correlations between IDO+ and Foxp3+
SIs. The survival times were compared using Kaplan-Meier
Survival analysis. The level of statistical signiﬁcance was set
at P<0.05.
3. Results
3.1. The Expression of IDO in Breast Cancer PTs and TDLNs
Was Higher Than That in Benign Diseases at Both RNA
and Protein Levels. The expression of IDO in 26 cases of4 Clinical and Developmental Immunology
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Figure 1: IDO expression in PTs and TDLNs was higher than that in benign diseases at both mRNA and protein levels. The expression of
IDO in 26 cases of breast cancer PTs, TDLNs, and normal adjacent tissues and 10 cases of benign breast diseases was detected using qRT-
PCR assay and IHC staining method. (a) The IDO mRNA expression in PTs was higher than that in benign diseases but lower than that in
TDLNs using the grayscale density ratio of IDO/β-actin (lane 1: IDO in PTs; lane 2: β-actin in PTs; lane 3: IDO in TDLNs; lane 4: β-actin in
TDLNs; lane 5: IDO in benign diseases; lane 6: β-actin in benign diseases; lane 7: IDO in normal tissues; lane 8: β-actin in normal tissues;
M: DL2000 marker). (b)–(e) The IDO protein was predominantly expressed on cancer cells in breast cancer PTs (b) and in myeloid cell-like
karyocytes in TDLNs (c), while less IDO expression was found in mammary ductal cells with hyperplasia in benign diseases (d). No IDO
p r o t e i ne x p r e s s i o nw a sd e t e c t e di nn o r m a la d j a c e n tt i s s u e s( e ) .
breast cancer PTs, TDLNs, and normal adjacent tissues and
10 cases of benign breast diseases was detected using qRT-
PCR and IHC methods. No detectable expression of IDO
was observed in the normal adjacent tissues at either RNA
or protein level (Figures 1(a) and 1(e)). The IDO mRNA
expression in PTs was about 3 times higher than that in
benign diseases by comparing the grayscale density ratio
of IDO/β-actin (Figure 1(a), P<0.05). Consistently, the
IDO+SR and IDO+SI in PTs were signiﬁcantly higher than
that in benign diseases, which were 46.15% (12/26) versus
10.00% (1/10) for IDO+SR and 13.16 ± 7.82% versus 3.24 ±
1.30% for IDO+SI (Figures 1(b) and 1(c), P<0.05). The
mRNA expression of IDO in TDLNs was 2 times higher
than that in PTs. Accordingly, the IDO+SR and IDO+SI in
TDLNs were signiﬁcantly higher than those in PTs which
were 73.08% (19/26) versus 46.15% (12/26) for IDO+SR and
20.46 ± 6.57% versus 13.16 ± 7.82% for IDO+SI (Figures
1(b)–1(d), P<0.05). Furthermore, we found that the IDO+
SIs in TDLNs were signiﬁcantly positively correlated to those
in PTs in a linear pattern as determined using the Regression
Analysis (r2 = 0.28, P<0.05). Furthermore, all TDLNs col-
lected from IDO+ p r i m a r yt u m o r sw e r ep o s i t i v ef o rI D O
staining when we used immunohistochemical cut-oﬀ value
of 10% for IDO+ tumor cells. The mean IDO+SIs in positive
tumors and corresponding TDLNs were 26.47 ± 14.12%
and 33.97 ± 13.91%, respectively. Contrarily, the mean
IDO+SIsinnegativetumorsandcorrespondingTDLNSwere
5.56 ± 2.54% and 7.25 ± 3.43%, respectively. Therefore,
comparing to the IDO− tumors, the TDLNs collected from
IDO+ tumors displayed higher level of IDO expression(P<
0.05) which had no correlation with the pathological type
and multiple receptors(ER/PR/Her2) status of the primary
tumors. However, higher IDO+S I sw e r eo b s e r v e di nt h e
metastatic TDLNs comparing to the nonmetastatic TDLNs,
whichwere34.41 ±15.18%versus21.45 ±9.76%(P<0.05).
This result was consistent with the increase of IDO+ myeloid
cell-like karyocytes and cancer cells in metastatic TDLNs.
3.2. The Expression of IDO in Breast Cancer PTs Was Positively
AssociatedwiththeClinicalStagingandLymphNodeMetasta-
sis of Tumors. In order to evaluate the clinical signiﬁcance of
IDOexpressioninbreastcancerPTs,aunivariateanalysiswas
performed between the IDO+SI in PTs and corresponding
clinical and pathological information of the same patient.
As shown in Table 2,h i g h e rI D O +SI correlated with more
advanced clinical staging and more extensive TDLNs metas-
tasis. The IDO+SI in stage III breast cancer was signiﬁcantly
higher than those in stage II or stage I breast cancer, whichClinical and Developmental Immunology 5
Table 2: The relationship between IDO expression and clinical
pathological indexes.
N IDO+SI (%) P value
Age (years)
<60 18 12.30 ± 8.35 0.465
≥60 8 15.11 ± 10.75
Menstrual status
Postmenopausal 14 15.02 ± 10.93 0.257
Nonpostmenopausal 12 10.83 ± 5.42
Tumor diameter (cm)
≤2 7 11.89 ± 6.55 0.211
2∼5 15 13.43 ± 6.88
>5 4 14.38 ± 7.69
Clinical stage
I 2 8.95 ± 3.79 0.034
II 20 11.72 ± 6.48
III 4 22.47 ± 10.79∗
Pathological type
Invasive Ductal Ca. 21 13.62 ± 9.39 0.223
Others 5 11.23 ± 6.25
histological grade
I 8 10.73 ± 6.45 0.324
II 10 12.29 ± 7.28
III 8 13.71 ± 5.96
TDLNs metastasis
pN0 6 10.29 ± 5.23 0.046
pN1 14 11.42 ± 8.49
pN2 4 15.98 ± 7.14
pN3 2 28.35 ± 14.78∗
ER status
(−) 12 15.76 ± 10.58 0.394
(+) 14 12.70 ± 8.83
PR status
(−) 13 13.18 ± 8.02 0.624
(+) 13 15.29 ± 9.31
Her-2 status
(−) 18 11.69 ± 8.46 0.457
(+) 8 14.34 ± 10.23
∗Statistically signiﬁcant diﬀerence between the samples of advanced stage
(stage III) and earlier stage (stage II and stage I), as well as the signiﬁcant
diﬀerence between the samples with more extensive LN metastasis (pN3)
and less or no LN metastasis (pN0-2).
were 22.47 ± 10.79%, 11.72 ± 6.48%, and 8.95 ± 3.79%,
respectively (P<0.05). Similarly, the IDO+SI in breast
cancer with metastasis extended to N3 lymph nodes was
signiﬁcantly higher than those with metastasis limited to
N2 and N1 lymph node or without lymph node metastasis,
which were 28.35 ± 14.78%, 15.98 ± 7.14%, 11.42 ± 8.49%,
and10.29 ±5.23%,respectively(P<0.05).Incontrast,there
was no signiﬁcant correlation between the IDO+ SI in PTs
andotherclinicalandpathologicalindexes,suchasage,men-
strual status, tumor diameter, pathological type, histological
grade, and expression of ER, PR, or Her2.
All patients were followed up at a median of 5 years, and
the overall survival (OS) and time to progression (TTP) were
analyzed. The mean OS of the IDO+ patients was shorter
than that of the IDO− patients (59.50 ± 5.01m versus 86.15
± 3.22m), but the diﬀerence was not statistically signiﬁcant
(P value = 0.145). Similarly, the mean TTP of the IDO+
patients was shorter than that of the IDO− patients (46.84
± 3.29m versus 78.91 ± 2.79m), but the diﬀerence was not
statistically signiﬁcant (P = 0.147). Although it is diﬃcult to
demonstrate an inverse correlation between clinical progno-
sis and the IDO status, possibly due to the small sample size,
our results implied a comparably worse outcome in IDO+
breast cancer patients.
3.3. The Expression of IDO in Breast Cancer PTs Was Positively
Correlated with the Density of Tregs in PTs and TDLNs. The
Foxp3+ Tregs in PTs, TDLNs, benign disease, and normal
adjacent tissues were detected using IHC staining method.
Foxp3 protein was detected in the nuclei of lymphocytes
inﬁltrated into PTs and TDLNs, but seldom in benign breast
diseasesandinnormalbreasttissues(Figures2(a)–2(c)).The
Foxp3+ SIs in breast cancer PTs were signiﬁcantly higher
than those of benign breast diseases and normal breast
tissues, which were 3.50 ± 1.04%, 0.71 ± 0.42%, and 0.55 ±
0.34%, respectively, (P<0.05). In contrast, the Foxp3+
SIs in the PTs were signiﬁcantly lower than those in the
TDLNs which was 6.13 ± 2.31% (P<0.05). More Foxp3+
Tregs inﬁltrated in the PTs with higher expression of IDO
and corresponding TDLNs (Figures 2(d)–2(f)). Contrarily,
in the breast cancer PTs with lower expression of IDO or
absence of IDO expression, lower numbers of Foxp3+ Tregs
were detected (Figures 2(g)–2(i)). The scatter plots were
generated to display the correlation between IDO expression
and density of Foxp3+ Tregs either in PTs or TDLNs. The
results indicated that IDO expression in breast cancer was
linearly correlated to the density of Treg in the PTs and
TDLNs. Statistical analyses demonstrated that the IDO+ SIs
displayed a positive correlation with the Foxp3+ SIs in PTs
and TDLNs, with linear regression equations of Y = 0.832 +
0.140X (Y:F o x p 3 + SIs in PTs; X:I D O +SIs) (r2 = 0.449,
P<0.05, Figure 2(j))a n dY = 3.771 + 0.160X (Y:F o x p 3 +
SIs in TDLNs; X:I D O +SIs) (r2 = 0.324, P<0.05, Figure
2(k)), respectively.
3.4. The Proportion and Absolute Number of
CD4+CD25+CD127− Tregs in CD3+ TC e l l sI n c r e a s e dA f t e r
Coculturing with IDO/CHO Cells. The mRNA and protein
expression of IDO, as well as the catalytic activity of tryp-
tophan have been determined in CHO/IDO cells as reported
in our previous study [23]. The CD3+ T cells isolated from
PBMCs of breast cancer patients were cocultured with CHO/
IDO and CHO/EGFP cells in complete medium supple-
mented with 10% FBS and 50U/ml IL-2 for 7 days. The
proportions and absolute number of CD4+CD25+CD127−
Tregs in treated and untreated T cells were detected using
ﬂow cytometry. The proportion of Tregs in CD4+ Tc e l l s
increased from 3.43 ± 1.07% to 8.98 ± 1.58% after coculture
with CHO/IDO cells, which is higher than that after
coculture with CHO/EGFP cells (3.73 ± 1.12%) (P<0.05,6 Clinical and Developmental Immunology
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Figure 2: IDO expression in PTs was positively correlated with the density of Tregs in PTs and TDLNs. The Foxp3+ Tregs in PTs, TDLNs,
benign disease, and normal adjacent tissues were detected using IHC staining method. (a)–(c) The Foxp3 protein appeared in the nuclei
of lymphocytes inﬁltrated into PTs (a) and TDLNs, including nonmetastatic TDLNs (b) and metastatic TDLNs (c). (d)–(i) In the PTs with
higherexpressionofIDO(d),moreFoxp3+ TregsinﬁltratedintothePTs(e)andcorrespondingTDLNs(f).Incontrast,inthePTswithlower
or no expression of IDO (g), less Foxp3+ Tregs were detected in the PTs (h) and corresponding TDLNs (i). (j) and (k) Scatter plots were
generated to display the correlation between IDO expression in breast cancer (IDO+SIs in primary tumors) and the density of Foxp3+ Tregs
in PTs (Foxp3+SIs in primary tumors) or in TDLNs (Foxp3+SIs in TDLNs). The IDO+SIs displayed a positive correlation with the Foxp3+
SIs in PTs with a linear regression equation of Y = 0.832 + 0.140X (j). Accordingly, the IDO+SIs showed a similarly positive correlation with
the Foxp3+ SIs in TDLNs with a linear regression equation of Y = 3.771 + 0.160X (k).
Figures 3(a)–3(c)). The absolute number of Tregs in CD3+
T cells stimulated by CHO/IDO was 629 ± 110.6 cells/μL,
higher than that in the coculture with CHO/EGFP cells
(268 ± 80.6 cells/μL) and that in unstimulated control CD3+
T cells (308 ± 96.3 cells/μL) (P<0.05).
3.5. The Expression of Foxp3 in CD3+ TC e l l sW a sU p r e g u l a t e d
at Both mRNA and Protein Levels After Coculturing with
IDO/CHO Cells. The expression of Foxp3 gene at mRNA
and protein levels in treated and untreated T cells were
detected using qRT-PCR assay and Western Blot analysis.
After 7 days of coculture, the relative mRNA amount of
Foxp3 gene in the CD3+ T cells stimulated by the CHO/IDO
cells was 0.00056 ± 0.00012, which was signiﬁcantly higher
than that in the CD3+ T cells stimulated by the CHO/EGFP
cells (0.00023 ± 0.00005) and that in the unstimulated
CD3+ T cells control (0.00028 ± 0.00013) (P<0.05, Figures
4(a) and 4(b)). Furthermore, Foxp3 expression was exclu-
sively detected in the lysates of CD3+ T cells stimulated by
CHO/IDO cells, indicated by a 48 kD protein band reactive
to a Foxp3-speciﬁc monoclonal antibody (Figure 4(c)).
4. Discussion
High level of IDO expression has been found in many
malignanttumors,includingcolorectalcancer[24],endome-
trial cancer [25], lung cancer [26], ovarian cancer [27],
and renal carcinoma [28]. However, its expression pattern
in primary human breast cancer tissue has been seldomly
reported. In this study we found that IDO expression at
both mRNA and protein levels were signiﬁcantly higher in
breast cancer PTs and TDLNs than those in benign diseases.Clinical and Developmental Immunology 7
250
200
150
100
50
S
S
C
-
A
50 100 150 200 250
FSC-A
P1
CD4 PerCP-Cy5.5-A
P2
105 104 103 102 105
105
104
104
103
103
102
102
105
105
104
104
103
103
102
102
C
D
1
2
7
i
s
o
t
y
p
e
c
o
n
t
r
o
l
P
E
-
A
CD25 isotype control FITC-A
C
D
1
2
7
P
E
-
A
CD25 FITC-A
×103
250
200
150
100
50
S
S
C
-
A
×103
×103
Q1 Q2
Q3 Q4
Q1 Q2
Q3 Q4
(a)
P1
P2
105
105
104
104
103
103
102
102
C
D
1
2
7
i
s
o
t
y
p
e
c
o
n
t
r
o
l
P
E
-
A
CD25 isotype control FITC-A
105
105
104
104
103
103
102
102
C
D
1
2
7
P
E
-
A
CD25 FITC-A CD4 PerCP-Cy5.5-A
105 104 103 102
250
200
150
100
50
S
S
C
-
A
×103
250
200
150
100
50
S
S
C
-
A
50 100 150 200 250
FSC-A
×103
×103
Q1 Q2
Q3 Q4
Q1 Q2
Q3 Q4
(b)
P1
105
105
104
104
103
103
102
102
105
105
104
104
103
103
102
102
C
D
1
2
7
P
E
-
A
CD25 FITC-A
C
D
1
2
7
i
s
o
t
y
p
e
 
P
E
-
A
CD25 isotype FITC-A CD4 PerCP-Cy5.5-A
105 104 103 102
250
200
150
100
50
S
S
C
-
A
×103
250
200
150
100
50
S
S
C
-
A
50 100 150 200 250
FSC-A
×103
×103
Q1 Q2
Q3 Q4
Q1 Q2
Q3 Q4
P5
(c)
Figure 3: The proportion and absolute number of CD4+CD25+CD127− Tregs in CD3+ T cells increased after coculture with IDO/CHO
cells. CD3+ T cells isolated from PBMCs of breast cancer patients were cocultured with CHO/IDO or CHO/EGFP cells for 7 days to allow
inductionofTregs.TheproportionsandabsolutenumberofCD4+CD25+CD127− Tregsweredetectedbyﬂowcytometry.(a)Theproportion
of CD4+CD25+CD127− Tregs in the T cells treated with IDO− CHO/EGFP cells (P2 region represents CD4+ T cells; Q4 region represents
CD4+CD25+CD127− Tregs). (b) The proportion of CD4+CD25+CD127− T r e g si nt h eTc e l l st r e a t e dw i t hI D O + CHO/IDO cells (P2 region
represents CD4+ T cells; Q4 region represents CD4+CD25+CD127− Tregs). (c) The CD3+ control T cells (P5 region represents CD4+ T
cells; Q4 region represents CD4+CD25+CD127− Tregs). The ﬂow cytometry dot plots indicate data of one representative experiment. Each
experiment was repeated at least 3 times.
IDO was mainly expressed in cancer cells in breast cancer
PTs and expressed at lower levels in certain myeloid cell-
like karyocytes in TDLNs and hyperplastic ductal cells in
benigndiseases,butnotexpressedinnormaladjacenttissues.
Our results demonstrated that the IDO+SIs in breast cancer
PTs were signiﬁcantly higher in tumors of more advanced
stagesandwithmoreextensivelymphnodemetastasis,which
correlated with a comparably worse clinical outcome. These
results suggest that IDO may play a pivotal role in promoting
metastasis of breast cancer, as the IDO-positive breast cancer
cells seem to have a higher potential in migrating to axillary
lymph nodes than the IDO-negative ones.
The above results coincided with the previous reports
thatmoreextensiveIDOexpressioninprimarycancertissues
was associated with higher distant metastasis rate in clinic
[24, 25]. A study by Sakurai et al. indicated that high expres-
sionofIDOinbreastcancercorrelatedwithclinicalstageand
may therefore play a critical role in immunosuppression in
those patients [29]. However, the mechanisms involved in
this pathogenesis process remain unknown. It is proposed
that local T-cell-based immunotolerance induced by high
level of IDO in the tumor microenvironment might be
the predominant immunoregulatory mechanism facilitating
tumor metastasis [24]. As a tryptophan catabolic enzyme,8 Clinical and Developmental Immunology
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Figure 4: Foxp3 expression in CD3+ T cells was upregulated both at mRNA and protein levels after coculture with IDO/CHO cells. The
expression of Foxp3 gene at mRNA and protein levels in treated and untreated T cells were detected using qRT-PCR assay and Western Blot
method. (a) After 7 day coculture, the relative mRNA level of Foxp3 in the CD3+ T cells treated with the CHO/IDO cells was signiﬁcantly
higher than that in the CD3+ T cells treated with the CHO/EGFP control cells or untreated CD3+ Tc e l l s( l a n e1 :β-actin in the CD3+ T
control cells; lane 2: Foxp3 in the CD3+ T control cells; lane 3: β-actin in the T cells treated with CHO/IDO cells; lane 4: Foxp3 in the T cells
treated with CHO/IDO cells; lane 5: β-actin in the T cells treated with CHO/EGFP cells; lane 6: Foxp3 in the T cells treated with CHO/EGFP
cells; lane 7: DL2000 Marker. (b) The mRNA amount of Foxp3 in the CD3+ T cells stimulated by the CHO/IDO cells was signiﬁcantly higher
than that in the CD3+ T cells stimulated by the CHO/EGFP cells and the unstimulated CD3+ T cells control. (c) Foxp3 expression at protein
levelintreatedanduntreatedTcellsdetectedbyWesternBlotanalysis.Foxp3expressionwasexclusivelydetectedinthecelllysatesofCD3+ T
cells treated with CHO/IDO cells, indicating a 48kD protein band reactive to a Foxp3-speciﬁc monoclonal antibody (lane 1: Foxp3 in CD3+
T cells treated with CHO/IDO cells; lane 2: Foxp3 in CD3+ T cells treated with CHO/EGFP cells; lane 3: Foxp3 in control CD3+ Tc e l l s ) .
I D Oa n dm e t a b o l i t e sh a v eb e e nr e p o r t e da sk e yr e g u l a t o r si n
suppressing immune surveillance and inducing immunotol-
erance in several diseases [30]. Several mechanisms by which
IDO contributes to immune escape have been identiﬁed.
IDO suppresses proliferation of T cells by hampering cell
cycle in mid-G1 phase [31]. IDO also promotes apoptosis
of activated T cells which were more sensitive to Fas-
dependent apoptosis after tryptophan deprivation [32]. Fur-
thermore, IDO has been reported to inhibit T-cell-mediated
immune response by directly inducing the diﬀerentiation
of CD4+CD25− T cells into CD4+CD25+ Tregs, or directly
activating mature Tregs [33].
CD4+CD25+ Tregs are a subset of regulatory T cells with
potent inhibitory eﬀects on innate and adaptive immunity
both in physiological and pathological status which play
important roles in tumor evasion and metastasis [34, 35]. It
iscurrentlyacceptedthatFoxp3isthemostspeciﬁcmarkerin
Tregswhichplayscrucialrolesinthegenerationandfunction
of Treg [36]. In our study, the Foxp3+ SIs in breast cancer
PTs were signiﬁcantly higher than those in benign diseases
and normal adjacent tissues, but lower than those in the
TDLNs which showed the same pattern as the IDO+SIs.
Therefore, we studied the correlation between the expression
levels of IDO and the density of Tregs both in breast cancer
PTs and TDLNs. Our data demonstrated that in the IDO-
positive breast cancer samples, more Tregs inﬁltrated into
the PTs and TDLNs, compared to the IDO-negative ones.
In addition, the expression of IDO in breast cancer PTs was
positively linearly correlated to the density of Treg in the PTs
and TDLNs in linear regression analysis. To ﬁnd out if high
level of IDO could induce ampliﬁcation of Foxp3+Tregs, we
cocultured CD3+ T cells with IDO+ CHO(IDO/CHO) cells
in vitro. We found that the proportion and absolute number
of CD4+CD25+CD127− Tregs increased after coculturing
CD3+ T cells with IDO/CHO for 7 days in which Foxp3 ex-
pression was upregulated at both mRNA and protein levels.Clinical and Developmental Immunology 9
These results implied that upregulated IDO in CHO cells
might favor ampliﬁcation of CD4+CD25+CD127 Tregs and
induce increasing expression of Foxp3 both in vivo and vitro
which coincided with the previous report that the long-term
eﬀect of the catabolic products of tryptophan is to enable
the regulatory function of CD4+CD25− T cells by inducing
Foxp3 expression and secreting inhibitory cytokine TGF-β
[37].
It is has been indicated that the interaction between IDO
and Tregs is a mutual eﬀect, in which high level of IDO
promotes the diﬀerentiation, activation, and maturation of
Tregs; conversely, the CTLA4 constitutively expressed on
CD4+CD25+ Tregs signiﬁcantly stimulates synthesis and
increases enzyme activity of IDO by binding to CD80/CD86
on dendritic cells (DCs) [38]. This theory was supported
by the observations from Munn’s group which indicate that
overexpression of IDO in antigen-presenting cells (APCs)
was the major cause of tumor-derived immune tolerance in
local lymph nodes of patients with breast cancer or melano-
ma [39]. Consistently, in this study we also observed that
some IDO high-expressing myeloid cell-like karyocytes in
TDLNs displayed positively linear correlation to the IDO
expression on cancer cells in PTs, which might participate in
the mutual cross-talk between IDO+ cancer cells and Foxp3+
Tregs and further magniﬁed the immunosuppressive cascade
triggered by IDO.
However, Jacquemier et al. reported an opposite eﬀect of
IDO in medullary breast cancer (MBC), a subtype of basal-
likebreastcancerdiﬀerentfrominvasivecarcinoma,inwhich
highexpressionofIDOinstromalorepithelialcellswasasso-
ciatedwithlargeamountoflympoidinﬁltrateandafavorable
clinicaloutcomeofpatients[40].Thisreport,however,stated
that the beneﬁcial prognosis of IDO+ tumors was exclusively
observedinbasal-likebreastcancer,butnotinothersubtypes
of breast cancer. Therefore, the discrepancy between this
previous study and ours may be attributed to the diﬀerent
pathological subtypes of breast cancer examined. In our
study, most samples were invasive ductal or lobular carci-
nomas, and no basal-like breast cancers are included. Our
conclusion is consistent with the study of Mansﬁeld et al.
using 47 cases of breast cancer samples, including 25 invasive
ductal carcinoma and 18 invasive lobular carcinoma, where
IDO+ sentinel lymph nodes accompanied by inﬁltration of
Foxp3+ Tregs imply lymph node metastasis of breast cancer,
and are therefore regarded as a negative prognostic factor
[12].
In conclusion, our study implied that upregulation of
IDO in breast cancer cells might inhibit local immune
surveillance by favoring ampliﬁcation and inﬁltration of
CD4+CD25+ Tregsin thetumormicroenvironment andthus
promote metastasis and relate to a bad prognosis. Therefore,
novel and eﬃcient IDO-targeted therapies may provide a
new strategy of breast cancer treatment.
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